Kernicterus Treatment Market Report 2024: Insights and Future Directions

The kernicterus treatment market size has grown steadily in recent years. It will grow from $2.88 billion in 2023 to $2.98 billion in 2024 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to improvements in neonatal care practices, increased awareness among healthcare professionals, government initiatives for maternal and child health, research funding and clinical trials, collaborations in medical research..

The kernicterus treatment market size is expected to see steady growth in the next few years. It will grow to $3.29 billion in 2028 at a compound annual growth rate (CAGR) of 2.6%. The growth in the forecast period can be attributed to continuous medical education programs, global health policies and initiatives, patient advocacy and support groups, international collaboration in pediatric research, government funding for neonatal health.. Major trends in the forecast period include advancements in neonatal jaundice monitoring technologies, introduction of phototherapy devices with enhanced features, development of bilirubin-reducing medications, focus on home-based phototherapy solutions, implementation of bilirubin nomograms and guidelines, integration of telehealth for remote monitoring..

Market Overview -
Kernicterus is a rare neurological condition that can occur in newborns with severe jaundice, a condition characterized by high levels of bilirubin in the blood. Kernicterus treatment refers to the medical interventions, therapies, and supportive care provided to individuals, typically infants and children. This treatment aims to address kernicterus's symptoms, complications, and long-term effects and improve the quality of life for affected individuals.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=13470&type=smp

Significant Role Of Neonatal Jaundice Prevalence In Driving the Kernicterus Treatment Market Growth
The prevalence of neonatal jaundice is driving the growth of the kernicterus treatment market going forward. Neonatal jaundice, also known simply as jaundice in newborns, is a common and typically harmless condition characterized by the yellowing of a baby's skin and the whites of their eyes. Kernicterus treatment is commonly used for neonatal jaundice; it manages the symptoms and provides supportive care. This procedure removes blood from the baby and replaces it with blood with a lower bilirubin level, improving the affected child's quality of life. For instance, in August 2023, according to reports published by the National Library of Medicine, a US-based biomedical library, globally, about 1.1 million babies each year develop severe neonatal hyperbilirubinemia (neonatal jaundice). Furthermore, in February 2021, according to ClinMed International Library, a US-based publishing company, it was estimated that at least 114,000 infants die yearly from neonatal hyperbilirubinemia (neonatal jaundice). Therefore, the prevalence of neonatal jaundice is expected to propel the growth of the kernicterus treatment market.

Competitive Landscape -
Major companies operating in the kernicterus treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd , Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, AstraZeneca plc., Abbott Laboratories, Sanofi SA, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Johnson and Johnson Private Limited, Baxter International Inc., Grifols S.A, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., CSL Limited, Glenmark Pharmaceuticals Ltd., Cipla Inc., Torrent Pharmaceuticals Ltd., Octapharma Brasil Ltda, Kedrion S.p.A, Biotest AG, Wockhardt Ltd., Mylan N.V., Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., China Biologic Products Holdings Inc.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.